Endoscopic retrograde cholangiopancreatography (ERCP) is a technique that uses X-rays to view the patient's bile and pancreatic ducts. It is an important examination method in the diagnosis and treatment of pancreaticobiliary diseases. In the US alone, the procedure is performed on average 40,000 per year. Post-ERCP pancreatitis (PEP) is a form of acute pancreatitis that occurs after an ERCP procedure in ca. 10% of patients. The complication can be fatal and elongate the time of hospitalization even further (mean length of stay for ERCP is 7 days). A recent study by Tadehara et al. showed that serum lipase is the preferable method for the early diagnosis of PEP that could allow earlier therapeutic interventions. This could improve patient outcomes, as well as shorten patient hospitalization. Lipase can be measured quantitatively in serum by a clinical chemistry test. DiaSys offers Lipase DC FS, a state-of-the-art direct colorimetric assay that determines lipase in serum and plasma. The reagent has an extended shelf-life, excellent performance and applies to various clinical chemical analyzers.
Lipase for early diagnosis of post-ERCP pancreatitis
Tadehara, M., Okuwaki, K., Imaizumi, et al. Usefulness of serum lipase for early diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis. World Journal of Gastrointestinal Endoscopy, 2019; 11(9), 477. doi: 10.4253/wjge.v11.i9.477
Ahmed, M., Kanotra, R., Savani, et al. Utilization trends in inpatient endoscopic retrograde cholangiopancreatography (ERCP): a cross-sectional US experience. Endoscopy international open, 2017, 5(04), E261-E271.